Bradley J Monk

43PUBLICATIONS
253CO-AUTHORS
Molecular targetsOncology and carcinogenesis not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersGlycoconjugates
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (43)

|Jan 14, 2026
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.

Robert L Coleman, Rodney Rocconi, Bradley J Monk

|Jul 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.

Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer

|Jul 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.

Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian

|Jul 01, 2025
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis.

Yong-Man Kim, Shin Nishio, Se Ik Kim

|Dec 05, 2024
Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.

Hailei Zhang, Anna Rutkowska, Antonio González-Martín

|Nov 05, 2024
Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States.

Bradley J Monk, Sophie van Mens, Oliver Hale

Pageof 8

Frequent Collaborators

9 joint publications

David M O'Malley

9 joint publications

Mansoor Raza Mirza

8 joint publications

Domenica Lorusso

8 joint publications

Robert L Coleman